000078 ST海王生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入11,299,187-21.05%26,667,70930,317,28836,418,77037,834,859
减:营业总成本11,377,512-20.35%26,741,85230,630,05836,503,98437,782,459
    其中:营业成本10,249,847-21.03%24,209,62327,444,70732,865,44534,045,035
               财务费用226,319-24.31%613,669806,282943,621905,212
               资产减值损失(8,447)-411.51%(126,427)(518,749)(962,355)(550,406)
公允价值变动收益2,4983,420.74%11,9956,38417,75256,847
投资收益(36,895)-141.53%8,92111,147(45,418)(143,505)
    其中:对联营企业和合营企业的投资收益(1,308)-522.30%5,8694,318(26,996)(106,917)
营业利润(174,926)-238.02%(504,929)(1,062,938)(1,468,030)(854,588)
利润总额(174,669)-231.66%(499,300)(1,081,694)(1,458,474)(853,160)
减:所得税费用27,732-59.13%53,25685,617260,559138,290
净利润(202,401)-412.24%(552,556)(1,167,311)(1,719,033)(991,450)
减:非控股权益1,551-95.32%10,50426,104(29,088)35,519
股东净利润(203,952)-743.75%(563,060)(1,193,415)(1,689,945)(1,026,969)

市场价值指针
每股收益 (元) *-0.078-745.83%-0.214-0.454-0.642-0.391
每股派息 (元) *------------
每股净资产 (元) *0.389-44.08%0.4660.6821.0921.705
审计意见 #--保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容